ES2180784T3 - Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo. - Google Patents

Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo.

Info

Publication number
ES2180784T3
ES2180784T3 ES96919971T ES96919971T ES2180784T3 ES 2180784 T3 ES2180784 T3 ES 2180784T3 ES 96919971 T ES96919971 T ES 96919971T ES 96919971 T ES96919971 T ES 96919971T ES 2180784 T3 ES2180784 T3 ES 2180784T3
Authority
ES
Spain
Prior art keywords
compositions
circulation
mixed micelles
blood
mri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919971T
Other languages
English (en)
Inventor
Herve Tournier
Bernard Lamy
Roland Hyacinthe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Research SA
Original Assignee
Bracco Research SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Research SA filed Critical Bracco Research SA
Application granted granted Critical
Publication of ES2180784T3 publication Critical patent/ES2180784T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES DE CONTRASTE DE FORMACION DE IMAGENES POR NMR QUE CONTIENEN ESPECIES QUE RESPONDEN MAGNETICAMENTE UNIDAS A MATERIALES DE BASE ORGANICOS ANFIPATICOS FISIOLOGICAMENTE ACEPTABLES A MODO DE MICELAS MIXTAS SUSPENDIDAS O DISPERSADAS EN UN SOPORTE LIQUIDO ACUOSO FISIOLOGICAMENTE ACEPTABLE. LAS COMPOSICIONES SON PARTICULARMENTE UTILES PARA INVESTIGACIONES DE DIAGNOSTICO DE BOLSAS DE SANGRE. LA INVENCION TAMBIEN SE REFIERE A LA PREPARACION DE LAS MICELAS MIXTAS, ASI COMO A COMPOSICIONES INYECTABLES QUE CONTIENEN LAS MICELAS MIXTAS COMO AGENTES DE CONTRASTE PARA MRI. UNA VEZ INYECTADAS, LAS MICELAS MIXTAS DE LAS COMPOSICIONES SE COMPORTAN COMO INTENSIFICADORES DEL CONTRASTE PARA LA FORMACION DE IMAGENES, EJ. MEJORARAN LA CALIDAD Y LA RESOLUCION DE LAS IMAGENES PROCESADAS ELECTRONICAMENTE OBTENIDAS DURANTE EXAMENES POR MRI DE LA CIRCULACION Y/O DE LOS ORGANOS DE LA CIRCULACION SELECCIONADOS. LAS COMPOSICIONES SE FORMULAN PARA PROTEGER A LAS PARTICULAS DE LOS AGENTES DE CONTRASTE CONTRA UNA RETIRADA ANTICIPADA POR PARTE DEL SISTEMA RETICULOENDOTELIAL (RES) DEL HIGADO Y DEL BAZO, DE MODO QUE PERMANEZCAN EN CIRCULACION DURANTE UN PERIODO DE TIEMPO SUFICIENTE COMO PARA PODER TOMAR UNA IMAGEN CORRECTA DE LOS VASOS SANGUINEOS Y SEAN TRANSPORTADOS A LOS ORGANOS SELECCIONADOS. LA FORMACION DE IMAGENES POR MRI DE LA CIRCULACION Y DE LOS ORGANOS SELECCIONADOS PUEDE AYUDAR EN GRAN MEDIDA EN EL DIAGNOSTICO DE POSIBLES SUFRIMIENTOS DE PACIENTES HUMANOS Y ANIMALES.
ES96919971T 1995-06-15 1996-06-14 Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo. Expired - Lifetime ES2180784T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95810403 1995-06-15

Publications (1)

Publication Number Publication Date
ES2180784T3 true ES2180784T3 (es) 2003-02-16

Family

ID=8221760

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919971T Expired - Lifetime ES2180784T3 (es) 1995-06-15 1996-06-14 Composiciones para formacion de imagen de un fondo de sangre, utilizacion y metodo.

Country Status (13)

Country Link
US (1) US5833948A (es)
EP (1) EP0804251B1 (es)
JP (1) JP4335976B2 (es)
KR (1) KR100399712B1 (es)
AT (1) ATE224737T1 (es)
AU (1) AU708328B2 (es)
CA (1) CA2195633C (es)
DE (1) DE69623929T2 (es)
ES (1) ES2180784T3 (es)
NO (1) NO314127B1 (es)
PT (1) PT804251E (es)
WO (1) WO1997000087A1 (es)
ZA (1) ZA965101B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6342598B1 (en) 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
IT1304501B1 (it) * 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
JP5078212B2 (ja) 2000-06-02 2012-11-21 ブラッコ・スイス・ソシエテ・アノニム 内皮細胞を標的とするための化合物、それを含む組成物およびその使用方法
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20060073197A1 (en) * 2004-05-20 2006-04-06 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US20070128253A1 (en) * 2005-04-13 2007-06-07 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
EP1590006B1 (en) 2003-02-04 2010-09-08 Bracco Suisse SA Ultrasound contrast agents and process for the preparation thereof
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2005063304A2 (en) * 2003-12-24 2005-07-14 Board Of Regents, The University Of Texas_System Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
WO2006018433A1 (en) 2004-08-18 2006-02-23 Bracco Research Sa Gas-filled microvesicles composition for contrast imaging
FR2883562B1 (fr) 2005-03-24 2009-02-27 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie
CA2603437A1 (en) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Poly(peptide) as a chelator: methods of manufacture and uses
US20090130018A1 (en) * 2005-05-31 2009-05-21 Accardo Antonella Supramolecular aggregates containing chelating agents and bioactive peptides as effective and selective delivery tools for drugs and contrast agents in mri or nuclear medicine
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
AU2007293888B2 (en) 2006-09-05 2013-05-02 Bracco Suisse S.A. Gas-filled microvesicles with polymer-modified lipids
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20090074751A1 (en) * 2007-09-18 2009-03-19 Ramaekers Nutrition, Inc. Growth factor fraction compositions and methods
KR101401217B1 (ko) * 2007-11-07 2014-05-28 충남대학교산학협력단 Ｐｅ－ｄｔｐａ의 새로운 용도
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009070788A1 (en) * 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions and methods for enhancing fertility
JP5647007B2 (ja) 2008-01-30 2014-12-24 ヒストジェン インコーポレイテッド 細胞外マトリックス組成物
EP2398503B1 (en) * 2009-02-13 2018-10-31 University Of Washington Gadolinium expressed lipid nanoparticles for magnetic resonance imaging
WO2010139003A1 (en) * 2009-06-01 2010-12-09 Commonwealth Scientific And Industrial Research Organisation Chelating amphiphiles
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
CN104602715A (zh) 2012-09-07 2015-05-06 伯拉考成像股份公司 用于MRI的包含金属两亲配合物的顺磁性固体脂质纳米颗粒(pSLN)
DK2892547T3 (da) 2012-09-10 2020-10-26 Xencor Inc Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser
JP6313329B2 (ja) 2012-12-21 2018-04-18 ブラッコ・スイス・ソシエテ・アノニムＢｒａｃｃｏ Ｓｕｉｓｓｅ ＳＡ ガス封入マイクロベシクル
US11352606B2 (en) 2014-02-10 2022-06-07 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
AU2016275149A1 (en) 2015-06-12 2018-01-04 Georgia State University Research Foundation Compositions and methods for treating opioid tolerance
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387410A (en) * 1983-03-18 1995-02-07 Mallinckrodt, Inc. Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
JPH06507904A (ja) * 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging

Also Published As

Publication number Publication date
KR100399712B1 (ko) 2004-02-18
NO970665D0 (no) 1997-02-13
EP0804251B1 (en) 2002-09-25
CA2195633C (en) 2008-09-16
ZA965101B (en) 1997-01-22
PT804251E (pt) 2003-01-31
JPH10504044A (ja) 1998-04-14
EP0804251A1 (en) 1997-11-05
NO314127B1 (no) 2003-02-03
DE69623929D1 (de) 2002-10-31
AU708328B2 (en) 1999-08-05
US5833948A (en) 1998-11-10
KR970704477A (ko) 1997-09-06
AU5843196A (en) 1997-01-15
DE69623929T2 (de) 2003-05-15
NO970665L (no) 1997-04-03
CA2195633A1 (en) 1997-01-03
ATE224737T1 (de) 2002-10-15
JP4335976B2 (ja) 2009-09-30
WO1997000087A1 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
ZA965101B (en) Blood-pool imaging compositions use and method
IL125895A0 (en) The use of an image enhancing moiety in the preparation of bioactivated nmr or optical imaging contrat agent from a prodrug
ES2152932T3 (es) Particulas de apatita tratadas para tecnicas de imagen para diagnostico medico.
EP0994352A3 (en) Contrast agent enhanced magnetic resonance imaging of myocardial tissue
Tournissac et al. Cranial window for longitudinal and multimodal imaging of the whole mouse cortex
Chin et al. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants
US20170112947A1 (en) Composition for use in imaging
Sumiyoshi et al. Sexual differentiation of the adolescent rat brain: a longitudinal voxel-based morphometry study
Watanabe et al. The usefulness of 3D MR angiography in surgery for ruptured cerebral aneurysms
Ohta et al. MicroCT for high‐resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice
Gorospe et al. Ewing’s sarcoma of the mandible: radiologic features with emphasis on magnetic resonance appearance
Halimi et al. Post-traumatic diabetes insipidus: MR demonstration of pituitary stalk rupture
EP1139113A3 (en) Combination of fluid complex images acquired using magnetic resonance imaging
NO964501L (no) Liposomsuspensjoner som blod-pool bildekontrastmidler
Getzmann et al. Impact of acceleration on bone depiction quality by ultrashort echo time magnetic resonance bone imaging sequences in medication-related osteonecrosis of the jaw
Ito et al. Development of agents for reinforcement of fluorescence on near-infrared ray excitation for immunohistological staining
Saito et al. Visualization of mouse spinal cord microscopic structures by use of ex vivo quantitative micro-CT images
Lutsep et al. Does reversal of ischemia on diffusion‐weighted imaging reflect higher apparent diffusion coefficient values?
Chen et al. MRI of alveolar soft-part sarcoma
Chhem Paleoradiology: history and new developments
Fujisawa et al. MR imaging findings in the posterior pituitary gland
Shirakuni et al. Magnetic resonance imaging of experimental brain edema in cats
Kalat et al. Internal anatomy of common carp (Cyprinus carpio) as revealed by magnetic resonance imaging
Tavares et al. Magnetic resonance imaging perfusion technique in the evaluation of achilles tendon injury in rabbits
Gates et al. Neuroimaging of fractureless transforamen magnum penetrating injury of the cerebellum